Hypercholesterolemia and Lipid-Lowering Therapy in Children and Adolescents With Type 1 Diabetes: Do We Implement Current Guidelines?
- 17 March 2026
- journal article
- Published by American Diabetes Association in Diabetes Care
- Vol. 49 (5) , 755-762
Abstract
OBJECTIVE: We investigated the prevalence of elevated LDL cholesterol in youth with type 1 diabetes (T1D), contributing factors, the frequency of lipid-lowering medication (LLM), and the achievement of target values. RESEARCH DESIGN AND METHODS: A cross-sectional analysis based on data from the Diabetes-Patienten-Verlaufsdokumentation registry (Diabetes Prospective Follow-up Registry) from 2013 to 2023. Inclusion criteria were T1D, age 2.6, >3.4, and >4.1 mmol/L were defined. Application of national and international treatment guidelines was examined. Descriptive analyses and linear and logistic regression models were implemented using SAS 9.4. RESULTS: The study included 55,028 participants. Of these, 9.7% and 2.3% had LDL >3.4 mmol/L and >4.1 mmol/L, respectively. The parameters HbA1c (β = 1,142.7; P = 0.001), female sex (β = 861.5; P < 0.001), and BMI >70th percentile (β = 520.1; P < 0.001) had the strongest effect on LDL levels. Only 7.3% of the cohort with elevated LDL levels received LLM. The majority (92.7%) with LDL >3.4 mmol/L and 87.0% with LDL >4.1 mmol/L were not treated. Estimated odds ratios (95% CI) for the use of LLM were 19.13 (15.4–23.7) for LDL >4.1 mmol/L; 3.1 (1.82–5.41) for ages 12–18 years; 2.31 (1.9–2.1) for diabetes duration of 5–10 years; 1.8 (1.5–2.1) for BMI >70th percentile; 1.3 (1.0–1.6) for HbA1c >9%; and 1.18 (1.0–1.4) for female sex. However, only 15.7% of the treated patients (n = 707) reached the LDL target of 3.4 mmol/L. CONCLUSIONS: We found a high prevalence of LDL hypercholesterolemia. The use of LLM was low, despite treatment indication, and treatment targets were mostly not achieved either due to underdosing or nonadherence to LLM. These findings confirm that dyslipidemia remains an underestimated cardiovascular risk factor in pediatric diabetology.Keywords
All Related Versions
Funding Information
- German Diabetes Association
- Diabetes-Stiftung (FP-0438-2021)
- German Robert Koch Institute
- German Federal Ministry for Education and Research within the German Center for Diabetes Research (82DZD14E03 and 82DZD14E1G)
This publication has 36 references indexed in Scilit:
- Sex differences in lipids: A life course approachAtherosclerosis, 2023
- Racial and Ethnic Cardiometabolic Risk Disparities in the Type 1 Diabetes Exchange Clinic Registry CohortEndocrine Practice, 2022
- Geographic variations in lipid-lowering therapy utilization, LDL-C levels, and proportion retrospectively meeting the ACC/AHA very high-risk criteria in a real-world population of patients with major atherosclerotic cardiovascular disease events in the United StatesAmerican Journal of Preventive Cardiology, 2021
- Non-HDL-cholesterol in an adolescent diabetes populationJournal of Clinical Lipidology, 2014
- Glucose Control Predicts 2-Year Change in Lipid Profile in Youth with Type 1 DiabetesThe Journal of Pediatrics, 2013
- Longitudinal Lipid Screening and Use of Lipid-Lowering Medications in Pediatric Type 1 DiabetesThe Journal of Pediatrics, 2007
- All-cause mortality rates in patients with type 1 diabetes mellitus compared with a non-diabetic population from the UK general practice research database, 1992–1999Diabetologia, 2006
- Early onset of subclinical atherosclerosis in young persons with type 1 diabetesThe Journal of Pediatrics, 2004
- Childhood risk factors predict adult risk associated with subclinical cardiovascular diseaseThe American Journal of Cardiology, 2002
- Prevalence and Phenotypic Distribution of Dyslipidemia in Type 1 Diabetes MellitusArchives of internal medicine (1960), 2000